DAVA Oncology (@davaonc) 's Twitter Profile
DAVA Oncology

@davaonc

DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.

ID: 2612301463

linkhttp://www.davaonc.com/ calendar_today08-07-2014 20:29:33

2,2K Tweet

1,1K Takipçi

1,1K Takip Edilen

DAVA Oncology (@davaonc) 's Twitter Profile Photo
DAVA Oncology
@davaonc

2 months ago

Dr. Haniel Araujo(haniel.araujo )MD Anderson Cancer Center outlined phase 1 results for zoldonrasib, an oral covalent RAS(ON)-G12D inhibitor: ORR 61 % in KRAS G12D NSCLC at the 1200 mg QD RP2D; median time-to-response 1.4 mo and mostly grade 1 AEs. RMC-LUNG-101 expansion is now enrolling.

Dr. Haniel Araujo(<a href="/_hanielaraujo/">haniel.araujo</a> )<a href="/MDAndersonNews/">MD Anderson Cancer Center</a> outlined phase 1 results for zoldonrasib, an oral covalent RAS(ON)-G12D inhibitor: ORR 61 % in KRAS G12D NSCLC at the 1200 mg QD RP2D; median time-to-response 1.4 mo and mostly grade 1 AEs. RMC-LUNG-101 expansion is now enrolling.